PIK3CA and neuroblastoma: Based on activation of the PI3K/mTOR pathway in a murine transgenic NB model expressing ALKF1174L and MYCN, we demonstrated that combining an ATP-competitive mTOR inhibitor with crizotinib induced tumor regression, although the molecular basis for this result was unclear at the time [6].